Interleukin-18 and IL-18BP in inflammatory dermatological diseases

Wang, Xiaoyun; Wang, Lian; Wen, Xiang; Zhang, Lu; Jiang, Xian; He, Gu

doi:10.3389/fimmu.2023.955369

Cited by 17 publications

(16 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current clinical application, IL-17 inhibitors (e.g., sekukizumab, eccilizumab) have a good effect on psoriasis. IL-18 has also been found to be the initiator of the cytokine cascade, and the concentration of IL-18 in serum correlates with the severity index (PASI) of psoriasis [ 22 , 83 ]. Recent data suggest that IFN-γ can sustain the progression of skin diseases [ 84 ].…”

Section: Discussionmentioning

confidence: 99%

Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis

Liu,

Zhou,

Yin

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Psoriasis is a systemic immune-mediated chronic inflammatory skin disease; its systemic manifestations and periodic recurrence negatively affect a patient’s quality of life. Inflammatory cytokines are known to have an important role in the onset and progression of psoriasis, however, data on the association between circulating inflammatory cytokines and psoriasis risk is inconclusive. Here, we explore the relevance of circulating proinflammatory factors to the pathogenesis of psoriasis using a meta-analysis. Objective To explore the association between circulating levels of inflammatory factors and psoriasis to elucidate the mechanisms underlying psoriasis and improve clinical diagnosis and treatment. Methods We systematically retrieved articles published in PubMed, EMBASE, the Cochrane Library and the Web of Science from the establishment of each database to January 2023. The standard mean difference (SMD) in cytokine levels of individuals with psoriasis and healthy controls was used to check for correlations between circulating inflammatory factor levels and psoriasis. Results Fifty-seven studies, with data from 2838 patients, were retrieved and included in the meta-analysis. Eleven inflammatory factors were studied (circulating interleukin-2 (IL-2), IL-4, IL-12, IL-17, IL-18, IL-22, IL-23, IL-35, IL-36, transforming growth factor-beta (TGF-β) and gamma-interferon (IFN-γ)). Of these, IL-2 [SMD = 1.29 (95% CI: 0.61–1.97; P <0.001)], IL-17 [SMD = 0.71 (95% CI: 0.12–1.30; P = 0.018)], IL-18 [SMD = 1.27 (95% CI: 0.64–1.90; P <0.001)], and IFN-γ [SMD = 1.90 (95% CI: 1.27–2.52; P <0.001)] levels had significant correlations with psoriasis. Conclusion Increased serum concentrations of the circulating inflammatory cytokines IL-2, IL-17, IL-18 and IFN-γ were significantly correlated with psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis

Liu,

Zhou,

Yin

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Another antibody that binds to IL-13 is Tralokinumab, approved for the treatment of moderate to severe atopic dermatitis from the age of 12 years. Phase III studies of the drug used for 16 weeks showed an improvement in the clinical condition in over 75% of patients, including approximately 30% of patients after monotherapy and 56% of patients after combination therapy with a class 3 local glucocorticosteroid [64,70,71].…”

Section: Atopic Dermatitis Therapymentioning

confidence: 99%

Potential Aspects of the Use of Cytokines in Atopic Dermatitis

Krupka-Olek,

Bożek,

Aebisher

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Atopic dermatitis (AD) is an abnormal inflammatory response in the skin to food, environmental IgE, or non-IgE allergens. This disease belongs to a group of inflammatory diseases that affect both children and adults. In highly developed countries, AD is diagnosed twice as often in children than in adults, which may possibly be connected to increased urbanization. The immune system’s pathomechanisms of AD involve humoral mechanisms with IgE, cellular T lymphocytes, dendritic cells occurring in the dermis, Langerhans cells occurring in the epidermis, and other cells infiltrating the site of inflammation (eosinophils, macrophages, mast cells, neutrophils, and basophils). Cytokines are small proteins that affect the interaction and communication between cells. This review characterizes cytokines and potential aspects of the treatment of atopic dermatitis, as well as new strategies that are currently being developed, including targeting cytokines and their receptors.

show abstract

“…This results in the production of pro-IL-18, which is subsequently released into the cytoplasm, where it undergoes activation. Eventually, IL-18 is transported to the extracellular space through cellular pores [44].…”

Section: Biology Of Il-18mentioning

confidence: 99%

“…Notably, IRAK1 and IRAK4 have been implicated in IL-18 signaling in Th1 and NK cells. These IRAKs further associate with the adaptor molecule TNF receptor-associated factor 6 (TRAF6), which in turn binds to the kinase TAK1 (transforming growth factor-b-activated kinase 1) [44]. TAK1 phosphorylates nuclear factor kappa B (NF-κB)-induced kinase (NIK), leading to NIK activation.…”

Section: Biology Of Il-18mentioning

confidence: 99%

See 1 more Smart Citation

Review of the Il-18 and IL37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets

Rusiñol,

Puig

2024

Preprint

View full text Add to dashboard Cite

Atopic dermatitis and psoriasis are prevalent inflammatory skin conditions with diverse treatment options. Despite advances in understanding their underlying mechanisms, recent research highlights the significance of interleukins IL-18 and IL-37 as potential therapeutic targets. This review synthesizes knowledge on these interleukins, their roles in atopic dermatitis and psoriasis, and emerging treatment strategies. Findings of a literature search up to May 30, 2024 underscore a research gap in IL-37-targeted therapies. Conversely, IL-18-focused treatments have demonstrated promise in adult-onset Still’s Disease, warranting further exploration for their potential efficacy in psoriasis and atopic dermatitis.

show abstract

Interleukin-18 and IL-18BP in inflammatory dermatological diseases

Cited by 17 publications

References 153 publications

Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis

Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis

Potential Aspects of the Use of Cytokines in Atopic Dermatitis

Review of the Il-18 and IL37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets

Contact Info

Product

Resources

About